Full Press Release Details
Services and Company Secretary Changes
Sydney, Australia - 1 May 2026 - Radiopharm
Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on
developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs advises, provides an update in accordance with
ASX Listing Rule 3.16.1.
the Company's annual reporting, it has a continuing agreement with Acclime Australia to provide company secretarial, CFO and statutory
reporting, accounting and financial management, bookkeeping and payroll processing services. Under this agreement, Mr Phillip Hains
was engaged as Chief Financial Officer and Joint Company Secretary.
The Company advises that Mr Hains has resigned
from his roles as Chief Financial Officer and Joint Company Secretary. The Board thanks Mr Hains for his contribution to the Company and
wishes him well in his future plans.
continue to engage Acclime Australia to provide these services, and Acclime Australia has nominated Mr Aaron Laurita to perform the responsibilities
of Chief Financial Officer. Mr Laurita brings strong finance and commercial expertise, developed through working with organisations across
several sectors, including the biotechnology sector, in Australia, the United States and Canada over the past decade. Mr Laurita holds
a Bachelor of Business (Professional Accountancy) from RMIT University and is a qualified Chartered Accountant and a member of Chartered
Accountants Australia and New Zealand.
also pleased to announce the appointment of Ms Amritha Sushil of Acclime Australia as Joint Company Secretary. Ms Sushil has extensive
experience in corporate governance and compliance, and the Board looks forward to her support in this role. Ms Sushil is a Chartered Secretary
and an Associate of the Governance Institute of Australia.
of Acclime Australia continues in his role as a Joint Company Secretary.
of ASX Listing Rule 12.6, the Company confirms that Ms Amritha Sushil and Mr Nathan Jong will serve as Joint Company Secretaries and will
be responsible for communications between the Company and ASX.
Authorized on behalf of the Radiopharm
Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
CEO & Managing Director
Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
Precision AQ (Formerly Stern IR)
Follow Radiopharm Theranostics:
Website - https://radiopharmtheranostics.com/
Twitter - https://twitter.com/TeamRadiopharm
InvestorHub - https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia